

# ACCEPTED VERSION

Courtney B. Subramaniam, Joanne M. Bowen, Marc A. Gladman, Maryam B. Lustberg, Samantha J. Mayo, Hannah R. Wardill

## **The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment**

Neuroscience and Biobehavioral Reviews, 2020; 116:470-479

© 2020 Elsevier Ltd. All rights reserved.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license  
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

Final publication at: <http://dx.doi.org/10.1016/j.neubiorev.2020.07.002>

### PERMISSIONS

<https://www.elsevier.com/about/policies/sharing>

Accepted Manuscript

Authors can share their [accepted manuscript](#):

18 Month Embargo

#### After the embargo period

- via non-commercial hosting platforms such as their institutional repository
- via commercial sites with which Elsevier has an agreement

In all cases [accepted manuscripts](#) should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license – this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our [hosting policy](#)
- not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article

**22 March 2022**

<http://hdl.handle.net/2440/127398>

## **The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment**

Courtney B. Subramaniam\* <sup>a</sup>, Joanne M. Bowen <sup>a</sup>, Marc A. Gladman <sup>b</sup>, Maryam B. Lustberg <sup>c</sup>, Samantha J. Mayo <sup>d</sup> and Hannah R. Wardill <sup>a, e</sup>

<sup>a</sup> Discipline of Physiology, Adelaide Medical School, University of Adelaide, South Australia, Australia

<sup>b</sup> Discipline of Anatomy & Pathology, Adelaide Medical School, University of Adelaide, South Australia, Australia

<sup>c</sup> Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA

<sup>d</sup> Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

<sup>e</sup> Department of Pediatric Oncology/Hematology, University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands

\* Corresponding Author: **Courtney Subramaniam**

[courtney.subramaniam@adelaide.edu.au](mailto:courtney.subramaniam@adelaide.edu.au); +61 8 8313 1537

Level 2 Helen Mayo Building South

University of Adelaide, Frome Rd

Adelaide 5005 AUSTRALIA

## **Abstract**

Chemotherapy-induced cognitive impairment (CICI) is an ill-defined complication of chemotherapy treatment that places a significant psychosocial burden on survivors of cancer and has a considerable impact on the activities of daily living. CICI pathophysiology has not been clearly defined, with candidate mechanisms relating to both the direct cytotoxicity of chemotherapy drugs on the central nervous system (CNS) and more global, indirect mechanisms such as neuroinflammation and blood brain barrier (BBB) damage. A growing body of research demonstrates that changes to the composition of the gastrointestinal microbiota is an initiating factor in numerous neurocognitive conditions, profoundly influencing both CNS immunity and BBB integrity. Importantly, chemotherapy causes significant disruption to the gastrointestinal microbiota. While microbial disruption is a well-established factor in the development of chemotherapy-induced gastrointestinal toxicities (largely diarrhoea), its role in CICI remains unknown, limiting microbial-based therapeutics or risk prediction strategies. Therefore, this review aims to synthesise and critically evaluate the evidence addressing the microbiota-gut-brain axis as a critical factor influencing the development of CICI.

**Keywords:** microbiome, chemotherapy, microbiota-gut-brain axis, chemotherapy-induced cognitive impairment, neuroinflammation

**Funding:** This work was supported by a Research Training Program Australia Stipend (CBS) and an NHMRC CJ Martin Biomedical Research Fellowship (HRW).

## **Introduction**

Chemotherapy is an integral part of cancer care for a variety of solid and non-solid tumours. It is routinely used in the neoadjuvant and adjuvant settings, with both curative and palliative intent [1]. Despite improvements in clinical efficacy, its use is limited by non-selective cytotoxicity and associated adverse effects impacting nearly all body systems [2]. Cognitive impairment is a particularly burdensome complication of chemotherapy, with neurocognitive symptoms affecting quality of life both during treatment and long after its cessation [3]. Cognitive symptoms are most commonly reported to affect processing speeds, memory, executive function, learning and concentration [4-7].

Critically, both the existence and impact of chemotherapy-induced cognitive impairment (CICI) has been underestimated by healthcare professionals in the past and has led survivors of cancer to question the existence of their symptoms, creating a significant psychosocial burden [8]. Standard neuropsychological testing often fails to capture the full breadth of symptoms and their impact on cancer survivorship. As such CICI remains an under-reported and enigmatic complication of chemotherapy with limited understanding among clinicians and researchers [8].

Despite considerable research interest over the past decade, the fundamental mechanisms underlying CICI are yet to be fully elucidated. Historically, research has focused on the direct cytotoxic properties of anti-cancer agents [10], although these have failed to form the basis for an effective CICI intervention. More recently, advances in our understanding of neurocognitive disease has supported neuroinflammatory-based

mechanisms. Importantly the immunomodulatory properties of the gastrointestinal microbiota, and its ability to control neuroinflammation, has gained increasing popularity as a factor thought to initiate the underlying pathology of various neurocognitive conditions [11].

In the setting of CICI, the extensive connections between the microbiota, the gastrointestinal system and the brain, known as the microbiota-gut-brain axis, presents as a novel mechanistic hypothesis, given that the microbiota is significantly disrupted during chemotherapy [12]. Furthermore, epidemiological data demonstrate overlap in gastrointestinal and neurological side effects in patients receiving chemotherapy, suggesting a common molecular basis [13]. Despite significant advances in our understanding of the microbiota-gut-brain axis in other neurocognitive diseases [14], the same level of appreciation has not been achieved for CICI, highlighting an area in need of enhanced understanding.

Given the chronicity of the symptoms and the increasing focus on optimising cancer survivorship and minimising late treatment effects, developing translational research techniques that identify methods of personalised risk prediction and targetable mechanisms to alleviate symptom burden for this complication is warranted. Therefore, the current review aims to synthesise and critically evaluate preclinical and clinical evidence addressing dysregulated microbiota-gut-brain communication in the context of CICI highlighting areas with translational potential in the provision of personalised cancer care.

## **The clinical relevance of CICI: prevalence and risk factors**

While CICI is experienced by almost all subsets of patients with cancer treated with chemotherapy, it has been most extensively characterised in individuals with breast cancer due to the high survival rates and unique characteristics of the chemotherapy agents typically used throughout treatment. A perceived cognitive decline, as determined by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) tool, was reported in 45% of individuals with breast cancer [15]. Although CICI is transient for most patients, with symptoms typically resolving 6-12 months following treatment cessation, there is evidence of these symptoms persisting up to 20 years post-chemotherapy in some individuals [16, 17].

Due to under-reporting, the subtle nature of cognitive symptoms and limitations of neurocognitive testing, risk factors for the development of CICI are poorly defined. Of the limited data available, increasing age, low baseline cognitive reserve, depression and anxiety prior to chemotherapy treatment are associated with elevated CICI risk [4, 15]. Single nucleotide polymorphisms of the catechol-O-methyltransferase (COMT) and apolipoprotein E (APOE) genes, which have known roles in cognitive function, have also been associated with CICI in survivors of breast cancer [10, 18]. However, this neuronal genetic predisposition and the aforementioned CICI risk factors fail to adequately account for the number of people developing CICI in survivors of breast cancer and other cancers.

The need for clinicians to evaluate cognitive ability post-treatment and refer those with signs of CICI for cognitive assessment, rehabilitation and group training has been

recognised by expert committees in published guidelines relating to the management of CICI [19]. While these guidelines are pivotal in improving the recognition of CICI as an important aspect of supportive cancer care, they fail to provide universal recommendations for the longitudinal monitoring of neurocognitive side effects or comprehensive management protocols for CICI, reflecting substantial inadequacies in our current understanding of CICI.

### **Pathobiology of CICI: current understanding and emerging candidates**

#### ***Anatomical observations:***

Imaging studies using standard and functional magnetic resonance imaging (MRI) have identified structural and metabolic changes in individuals with chemotherapy-treated breast cancer when compared to non-treated patients such as a decrease in overall left hippocampal volume, hyporesponsiveness of the dorsolateral prefrontal cortex during a task involving planning skills and significant alterations in cerebral blood flow to specific regions of the frontal cortex during a short term memory task [7, 20, 21]. Such changes were associated with decreases in executive function, specifically planning skills, and deficits in verbal memory respectively [7, 20]. Demyelination and decreased fibre density of frontal and temporal white matter tracks have also been detected using diffusion tensor imaging in individuals with chemotherapy-treated breast cancer, which may explain decreases in processing speeds [4, 22, 23]. Cancer itself is also known to cause cognitive impairment, although, the use of non-chemotherapy treated cancer patients as controls in these studies separates cancer-related cognitive impairment from CICI, suggesting that the structural and metabolic changes observed in the

hippocampus, pre-frontal cortex and white matter tracks are likely attributable to chemotherapy-related cytotoxicity.

***Molecular candidates:***

While imaging studies have provided critical insight into the central manifestations of CICI, the molecular mechanisms underpinning these changes are less clearly defined with other factors such as depression, anxiety, concurrent treatments (including radiation, hormone or immunotherapy), confounding our ability to pinpoint a distinct cause [3, 17, 24]. CICI molecular candidates may relate directly to the mechanism of action of traditional chemotherapy drugs. Such agents may result in DNA damage and associated deficits in DNA repair mechanisms, as well as telomere shortening of both neurons and supportive cells [10, 25]. The mechanism of action and neurocognitive side effects of common chemotherapy classes is displayed in Table 1. However, due to the use of combination chemotherapy for the treatment of solid and non-solid tumors, our ability to attribute neurocognitive side effects, observed in clinical studies, to specific classes of drugs is limited. The cognitive domains impaired following treatment with common chemotherapy regimens has been comprehensively described in a recent systematic review by *Huehnchen et al* [26]. Seeing as these are a direct result of chemotherapy agent mechanism of action, and thus efficacy, attention has now shifted to identifying other mechanisms of CICI that are potentially targetable.



### ***Emerging neuroinflammatory mechanisms:***

It is well documented that direct cytotoxic damage initiates secondary pathological mechanisms which serve to exacerbate off-target tissue injury, typically mediated by reactive oxygen species (ROS). In the context of CICI, indirect inflammatory based mechanisms have recently been proposed to contribute to symptomology, with particular focus on blood brain barrier (BBB) disruption and neuroinflammation [9].

Chemotherapeutic agents have long been considered unable to cross the BBB due to their molecular mass, a hypothesis based on their poor efficacy in treating CNS malignancies. However, evidence of systemically administered chemotherapeutic agents in the CNS contests this [27, 28]. Importantly, like other tight junction mediated barriers, the BBB is highly malleable with alterations in its permeability mediated by numerous physiological and pathological factors. Indeed chemotherapy agents, such as oxaliplatin and irinotecan, are able to alter BBB permeability [29, 30]. Similarly, numerous proinflammatory mediators which are known to be released in high levels during chemotherapy, such as tumour necrosis factor alpha (TNF $\alpha$ ) [31, 32], are also able to disrupt BBB integrity [33, 34]. Consequently, chemotherapy appears to be able to disrupt the BBB via direct and indirect mechanisms.

BBB damage, and a resulting increase in permeability, is a critical event in facilitating peripheral and central communication [33], with peripherally derived factors, such as proinflammatory cytokines or the chemotherapeutic agent itself, allowed access to the CNS, where they can initiate a neuroinflammatory response (see Figure 1) [35-39]. Accordingly, breakdown or disruption of the BBB is an important event in facilitating

microbiome-gut-brain axis communication, with microbial derived products able to gain direct access to the CNS. While the importance of the microbiome-gut-brain axis is accepted in various neurocognitive conditions [11], it is only recently emerging as a potential contributor to the underlying pathology of CICI [40] and thus a potential target in the provision of supportive cancer care and treatment of CICI.

### **The microbiota-gut-brain axis**

The gastrointestinal microbiota, a collection of bacteria, viruses, archaea and other microorganisms present within the gastrointestinal tract, is made up of almost one hundred trillion microorganisms [41]. This population evolved with humans and as such, a mutualistic relationship exists between a host and their indigenous microbes offering bidirectional benefits. The intimate connection which exists between the CNS and the gastrointestinal microbiota, termed the *microbiota-gut-brain axis* [42], is an extensive bidirectional communication system by which the microbiota can exert profound influence over the CNS, effecting behavioral, emotional and cognitive domains. Experimental evidence has revealed many potential pathways of communication between the microbiota and the brain, encompassing microbial-derived metabolites [43] and their impact on the neural, hormonal and immune-related signalling routes previously recognised as the gut-brain axis [44]

### ***Microbiota-brain communication***

*Microbial metabolites:* Gastrointestinal microbes are able to produce a variety of bioactive molecules, including neurotransmitters, facilitating neurochemical

communication between microbes and the host's CNS [45]. Short-chain fatty acids (SCFAs) can enter systemic circulation and may interact with the brain via this route [46] whereas transformed secondary bile acids and branched chain amino acids may influence brain function through regulating gastrointestinal barrier permeability and immune status [45, 47].

SCFAs appear to be of particular relevance to cognitive function as microbial-derived metabolites, produced through bacterial fermentation of dietary fibre [48], are capable of modulating CNS maturation, innate immunity and BBB permeability. In germ-free mice, maturation of microglia, the resident macrophages of the CNS, is significantly altered with markedly different gene expression profiles and abnormal morphology [49]. These microglia also show an inability to activate in response to viral or bacterial exposure, indicating that the presence of a functional microbiome is necessary for an appropriate CNS innate immune response to be mounted. Interestingly, the administration of the SCFAs (sodium propionate, sodium butyrate and sodium acetate) fully restored microglial maturity and function [49]. Similarly, the development and function of the BBB is severely altered in germ-free mice, with increased permeability due to reduced expression of occludin and claudin-5; two key junctional proteins that maintain a selective and semi-permeable barrier. Critically, recolonisation with conventional GI microbiota restored normal BBB permeability and tight junction protein expression [50]. Similarly, the SCFA sodium propionate prevented lipopolysaccharide-induced tight junction disruption *in vitro* [51]. Therefore, it is possible that SCFAs are important in mediating the influence of the microbiome over CNS innate immunity and BBB

permeability, both of which are likely to be important in explaining CICI development, as discussed above.

*Neural pathways:* The vagus nerve provides extensive innervation to the gastrointestinal tract and thus acts as a direct route for communication within the microbiota-gut-brain axis [52]. Microbes within the lumen of the small and large intestine are able to signal to vagal afferents directly or via a functional synapse with the intrinsic primary afferent neurons of the enteric nervous system [53, 54]. In experimental models where the composition of the microbiota has been altered, by direct small intestine infusion of *Lactobacillus rhamnosus* (now referred to as *Lacticaseibacillus rhamnosus* based on an updated taxonomic classification [55]) or in germ-free animals, both intrinsic primary afferent neurons and vagal afferents show altered firing patterns [54, 56]. In the context of CICI, vagal afferent signalling has been proposed to influence memory through a neural connection between the medial nucleus tractus solitarius and hippocampal neurons [57]. As such, it is possible that chronic changes to Vagal afferent signalling seen in response to microbial disruption, may impact memory, and thus cognitive function via this neural circuit. For a more comprehensive review, Breit *et al* [58] elegantly outline the role of the vagus nerve as a modulator of the gut-brain axis in both psychiatric and inflammatory disorders.

*Hormonal communication:* The hypothalamic-pituitary-adrenal (HPA) axis, which is primarily recognised for its role in coordinating the neuroendocrine response to stress, has also been implicated in microbiota-gut-brain communication [45]. A link between the HPA axis and the gastrointestinal microbiota was first established in germ-free mice,

which exhibited hyperactivity of the HPA axis when subjected to restraint stress [59]. It has long been recognised that stress and HPA activity are related to cognitive performance [60], with higher levels of activity, and associated cortisol levels, being linked to both lower cognitive performance [61] and a higher risk of developing diseases characterised by cognitive impairment, such as Alzheimer's disease [62]. Accordingly, it is possible that the gastrointestinal microbiota, and changes to microbial homeostasis, may influence cognitive function by disrupting the HPA axis and altering stress circuitry.

While the mechanisms by which the gastrointestinal microbiota influence cognition require further clarification, there is mounting evidence of a link between microbiota composition and various neurological functions, including mood and cognition [63, 64]. For example, there is a wealth of data supporting the beneficial effects of probiotics on symptoms in individuals with major depressive disorder [63]. A significantly altered microbiota composition has also been seen in individuals with Alzheimer's disease, linking certain microbial profiles with impaired cognitive function [64]. Whilst this interaction has not been well studied in the setting of supportive cancer care, emerging evidence suggests that the microbiota may in fact be a critical mediator of CICI.

### **Symptom clusters: the link between CNS and gastrointestinal side effects**

Perhaps the most convincing evidence suggesting the microbiota's contributory role in CICI development, is the mechanistic link proposed to exist between CICI and chemotherapy-induced gastrointestinal toxicity [9, 65, 66]. Gastrointestinal toxicity is an umbrella term used to describe the constellation of gastrointestinal symptoms caused by chemotherapy agents that includes diarrhoea, constipation, gastrointestinal bleeding

and pain, which largely result from cytotoxic injury to intestinal epithelial cells (clinically referred to as mucositis) [67]. The hypothesised link between CICI and gastrointestinal mucositis was built upon clinical observations of both neurological (memory, executive function and learning impairments) and gastrointestinal (diarrhoea, abdominal bleeding and pain) symptom clusters; a phenomenon whereby patients simultaneously present with both clusters of symptoms suggestive of common causes [13].

Experimentally, neurological and gastrointestinal symptom clusters have been observed with a study demonstrating the development of central neurotoxicity in a model of gastrointestinal mucositis [30]. Importantly, a more recent pre-clinical study has demonstrated a strong relationship in paclitaxel treated mice, between structural differences in colonic tissue, such as increased crypt depth, and microglial activation in the dentate gyrus and prefrontal cortex; two regions of the brain intrinsically linked with the symptoms of CICI [68]. Importantly, microbiota composition during chemotherapy treatment, and its interactions with the host's innate immune system, have been heavily implicated in the development of gastrointestinal mucositis [12, 69, 70].

### **Chemotherapy-microbiota interactions**

Recently, the direct relationship between non-antibiotic drugs and the microbiota has received significant attention, with evidence of changes to microbiota composition following the intake of drugs [71], and suggestions that the microbiota can influence the action of drugs, impacting metabolism and efficacy [72]. Importantly, gastrointestinal mucositis is characterised by significant microbial disruption [12, 69, 70] and aberrant immune signalling; both of which are compounded by other aspects of cancer therapy

including prophylactic and empirical antibiotic use, altered food/nutrition status (either cachexia or need for total parental nutrition) and the tumour microenvironment. While the exact microbial changes caused by chemotherapy vary in different patient cohorts, these changes are all largely underpinned by decreased diversity/richness and a shift towards a gram-negative dominated enterotype with deficiencies in the commensal taxa (such as *Lactobacillus*, *Bifidobacterium* and *Clostridium cluster XIV*) and expansion of pathobionts (including *Escherichia coli* (*E. coli*) *Staphylococcus* and *Bacteroidetes*) [73-80]. *Secombe et al* [12] provide a comprehensive review of the changes to microbial composition and its communication with the innate immune system during chemotherapy treatment.

While the specific changes vary, chemotherapy-induced microbial disruption impairs the protective, immunomodulatory effects that a diverse microbiota would normally provide to its host and increases the abundance of damaging products produced by pathogenic microbes. Of particular relevance to supportive cancer care and CICI is the increase in lipopolysaccharide, a key driver of intestinal inflammation via its interaction with toll-like receptor 4 [12]. Importantly, lipopolysaccharide is well recognised for its ability to degrade tight junction proteins, resulting in an increase in intestinal permeability enabling systemic translocation of lipopolysaccharide to peripheral circulation [81], where it is able to modulate BBB permeability, activate glia and induce neuroinflammation [33]. This mechanistic interaction between the gastrointestinal system and the brain has prompted investigation of the microbiome as a therapeutic target for CNS dysfunction, and subsequently the term 'psychobiotic' has been formed.

## **Psychobiotics and their relevance to CICI**

Whilst psychobiotics are strictly defined as a microbial intervention with psychological benefits to the host, probiotic interventions have also been shown to induce cognitive benefits and therefore may have relevance to the treatment of CICI. The impact of orally administered microbial strains on cognition has been elegantly demonstrated by numerous preclinical studies. Savignac et al. [82], showed that treatment with the gram-positive *Bifidobacterium longum* improved memory and learning in mice with anxiety. Furthermore, age-related deficits in hippocampal long term potentiation, a model of neuronal plasticity which may underlie memory consolidation, were attenuated in rats receiving the probiotic VSL#3, which contains 8 gram-positive bacterial strains [83]. In contrast, the gram-negative, enteric pathogen *Citrobacter rodentium* has been shown to induce memory and learning deficits in mice [84].

Currently, comprehensive clinical trials are lacking but small pilot studies have revealed promise for probiotic intervention as a potential treatment of cognitive impairment in various disease states. For example, multi-strain probiotic supplementation has been shown to improve cognitive function in a small number of individuals with Alzheimer's disease, hepatic encephalopathy and those who are HIV positive [85-87]. Furthermore, a three month daily regime of probiotic treatment in individuals with bipolar disorder improved executive function, attention and processing speeds [88]. While the results require validation, they highlight the influence that certain microbial strains can have on the CNS, reiterate the importance of microbial stability on neurocognitive function and thus warrant further investigation in the setting of CICI.



Despite the lack of interventional clinical trials, controlled studies have investigated changes to microbial composition and performance in various cognitive battery tools (Table 2). Within each study, distinct associations between microbial strains and good or poor cognitive performance were highlighted. However, these were not frequently replicated between studies, even when similar population groups were investigated [64, 89]. This could be related to the heterogeneity in what defines 'good' or 'poor' performance, the cognitive tests used and the cross-sectional design of these trials. Consequently, longitudinal studies would be beneficial in identifying microbial profiles associated with cognitive function over the course of different diseases. This could allow the development of probiotic treatments, in the same mold as psychobiotics, tailored specifically to cognitive deficits, and may be of use in treating CICI.

### **The microbiota-gut-brain axis in supportive cancer care: shortcomings and avenues for personalised care**

While the influence of microbiota composition over both cognition and the development of gastrointestinal mucositis is compelling, a role for the microbiota in CICI has not previously been reported. However, linkages between the microbiome and psychoneurological symptoms (a constellation of symptoms including depression, anxiety, fatigue and pain) in cancer have been identified and may provide insight into the microbiota's role in CICI. Recent findings have provided the first evidence for an association between post-treatment gastrointestinal microbiota and fear of cancer recurrence, a significant yet unmet psychological need of survivors of cancer [90]. Fear of cancer recurrence encompasses depression, anxiety and post-traumatic stress

related symptoms and while not necessarily impacting cognition, similar brain regions, such as the hippocampus, are involved in both fear of cancer recurrence and CICI. In survivors of breast cancer, severe fear of cancer recurrence was associated with lower microbial diversity, increased *Bacteroidetes* (gram-negative) and decreased *Firmicutes* (gram-positive) at phylum level [90]. Whilst only correlative with high order microbial taxa, these findings support the proposed role of chemotherapy-induced microbial disruption in CICI and highlights the need to understand the dynamics of the microbiota-gut-brain axis and its contribution to acute and chronic neurocognitive, cancer-related side effects.

The concept that an individual's unique microbiome composition determines their risk of disease and/or response to treatment/intervention is an increasingly popular hypothesis under investigation in a variety of clinical scenarios, including supportive cancer care [91]. For example, an individual's microbiome composition has been shown to predict their response to diet interventions, and therefore can be used to tailor dietary advice to the individual [92, 93]. This concept reflects the high degree of individualisation in the microbiome, reflecting the cumulative impact of host genetics and an increasingly long list of environmental factors known to profoundly shape the composition of the microbiome. In the setting of supportive cancer care, an individual's baseline microbiome has been directly correlated with outcomes of treatment, including radiation-induced-gastrointestinal toxicity, immunotherapy colitis and blood stream infection [94-96], with authors suggesting that an individual's microbial enterotype determines their baseline immune tone and sensitivity to inflammatory triggers.

Exploiting the microbiome as a potential risk predictor of chemotherapy-induced toxicities, including CICI, holds great clinical potential. A major obstacle in cancer therapy is the heterogeneity in treatment response, particularly in terms of treatment toxicity [12]. Despite intensive research efforts to uncover genetic reasons for this phenomenon, it remains largely unclear why some individuals with cancer are highly susceptible to toxicity and others are not. Based on current evidence and emerging mechanistic detail, the microbiome holds great promise in identifying patients at risk of toxicities, including CICI, enabling targeted and proactive supportive care interventions and tailored treatment regimens for high risk individuals [91]. This could involve identification of patients with cancer at risk of developing severe CICI based on their pre-treatment microbial profile, thus allowing for the management of this risk early in their treatment plan. Remodelling of their microbial profile to reduce risk could be achieved through the use of microbiota-targeted therapeutics, such as probiotics, prebiotics, postbiotics and faecal microbiota transplantation (FMT).

As discussed above, probiotic interventions, which deliver live exogenous microbes, have been shown to induce cognitive benefits in preclinical models [82, 83] and thus may have relevance in the treatment of CICI. Similarly, prebiotics and postbiotics, which deliver compounds promoting the beneficial activity of host microbes and microbiota-derived metabolites, respectively [97], may also have the potential to counteract the negative effects of chemotherapy treatment on microbiota composition. However, with heterogeneity in treatment response, achieving predictable outcomes on both the microbial community and host health using these therapies remains a significant challenge in need of further refinement [97].

FMT, which involves transfer of a faecal suspension into the gastrointestinal tract to manipulate microbiota composition, has proven to be more successful as a microbiota-based therapeutic [97, 98] and is now routinely used for the treatment of recurrent or refractory *Clostridium difficile* infection [99-101]. In the setting of clinical oncology, the use of FMT in the management of both treatment-related toxicities such as gastrointestinal mucositis and immunotherapy colitis, as well as secondary complications of therapy, specifically graft versus host disease and blood stream infection, has been proposed. However, this has been met with caution due to the immunocompromised status of individuals undergoing cancer therapy and the perceived risk of bacterial translocation and sepsis [98]. As such, the safety of FMT as an adjunctive supportive care intervention for individuals undergoing cancer therapy would need to be established in this population prior to it presenting as a viable treatment for CICI. Nevertheless, characterisation of the microbiota-gut-brain axis' role in CICI and identification of pre-treatment microbial profiles associated with CICI development, is necessary to fully appreciate how the microbiota could be targeted to prevent CICI in patients with cancer.

## **Summary**

Given the superior outcomes being achieved by cancer treatment, clinical focus has increasingly shifted to cancer survivorship and CICI is a significant complication of chemotherapy that requires wider acknowledgment. Further appropriate research efforts are warranted to better understand its pathobiology which, to date, remains unclear. A chronic state of increased BBB permeability and neuroinflammation is an attractive, and

increasingly convincing, hypothesis for the development of CICI. However, further investigation and comprehensive characterisation of the putative molecular mediators discussed is still required. Finally, although the microbiota-gut-brain axis has not been well studied in the setting of CICI, evidence linking the microbiome to cancer related outcomes, such as gastrointestinal mucositis, and other neurodegenerative conditions suggests that the microbiota may in fact be a critical mediator of CICI which warrants further attention.

### **Acknowledgements**

N/A

### **Declarations of interest**

Joanne Bowen has received research funding, unrelated to this review, from AstraZeneca, Helsinn Healthcare, Pfizer Pharmaceuticals, PanTheryx and Puma Biotechnology Inc.

### **Author Contributions**

**Courtney Subramaniam:** Writing – Original Draft; **Joanne Bowen:** Supervision, Writing – Review & Editing; **Marc Gladman:** Supervision, Writing – Review & Editing; **Maryam Lustberg:** Writing – Review & Editing; **Samantha Mayo:** Writing – Review & Editing; **Hannah Wardill:** Conceptualisation, Supervision, Writing – Review & Editing.

## References

1. Wigmore, *The effect of systemic chemotherapy on neurogenesis, plasticity and memory*. *Curr Top Behav Neurosci*, 2013. **15**: p. 211-40.
2. Nurgali, K., R.T. Jagoe, and R. Abalo, *Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?* *Front Pharmacol*, 2018. **9**: p. 245.
3. Holmes, D., *Trying to unravel the mysteries of chemobrain*. *Lancet Neurol*, 2013. **12**(6): p. 533-4.
4. Ahles, T.A., et al., *Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve*. *J Clin Oncol*, 2010. **28**(29): p. 4434-40.
5. Apple, A.C., et al., *Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns*. *Neuroimage Clin*, 2017. **14**: p. 685-691.
6. Apple, A.C., et al., *Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy*. *Neuroimage Clin*, 2018. **20**: p. 110-118.
7. Kesler, S.R., J.S. Kent, and R. O'Hara, *Prefrontal cortex and executive function impairments in primary breast cancer*. *Arch Neurol*, 2011. **68**(11): p. 1447-53.
8. Selamat, M.H., et al., *Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications*. *PLoS One*, 2014. **9**(9): p. e108002.

9. Wardill, H.R., et al., *Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction*. Int J Cancer, 2016. **139**(12): p. 2635-2645.
10. Ren, X., et al., *Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors*. Biochim Biophys Acta Mol Basis Dis, 2019.
11. Luczynski, P., et al., *Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior*. Int J Neuropsychopharmacol, 2016. **19**(8).
12. Secombe, K.R., et al., *The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity*. Int J Cancer, 2019. **144**(10): p. 2365-2376.
13. Aprile, G., et al., *Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy*. Cancer, 2008. **112**(2): p. 284-92.
14. Dinan, T.G. and J.F. Cryan, *The Microbiome-Gut-Brain Axis in Health and Disease*. Gastroenterol Clin North Am, 2017. **46**(1): p. 77-89.
15. Janelins, M.C., et al., *Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study*. J Clin Oncol, 2017. **35**(5): p. 506-514.

16. Koppelmans, V., et al., *Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy*. J Clin Oncol, 2012. **30**(10): p. 1080-6.
17. Lange, M. and F. Joly, *How to Identify and Manage Cognitive Dysfunction After Breast Cancer Treatment*. J Oncol Pract, 2017. **13**(12): p. 784-790.
18. Lengacher, C.A., et al., *Moderating Effects of Genetic Polymorphisms on Improvements in Cognitive Impairment in Breast Cancer Survivors Participating in a 6-Week Mindfulness-Based Stress Reduction Program*. Biol Res Nurs, 2015. **17**(4): p. 393-404.
19. Runowicz, C.D., et al., *American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline*. J Clin Oncol, 2016. **34**(6): p. 611-35.
20. de Ruiter, M.B., et al., *Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer*. Hum Brain Mapp, 2011. **32**(8): p. 1206-19.
21. Silverman, D.H., et al., *Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy*. Breast Cancer Res Treat, 2007. **103**(3): p. 303-11.
22. Deprez, S., et al., *Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients*. Hum Brain Mapp, 2011. **32**(3): p. 480-93.



23. Li, T.Y., et al., *Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis*. BMC Cancer, 2018. **18**(1): p. 1211.
24. McGinnis, G.J., et al., *Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model*. Oncotarget, 2017. **8**(6): p. 9155-9173.
25. El-Agamy, S.E., et al., *Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain*. Cancer Chemother Pharmacol, 2019.
26. Huehnchen, P., et al., *Cognitive impairment after cytotoxic chemotherapy*. Neurooncol Pract, 2020. **7**(1): p. 11-21.
27. Gangloff, A., et al., *Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel*. J Nucl Med, 2005. **46**(11): p. 1866-71.
28. Miura, Y., et al., *Evaluation of the targeted delivery of 5-fluorouracil and ascorbic acid into the brain with ultrasound-responsive nanobubbles*. J Drug Target, 2018. **26**(8): p. 684-691.
29. Branca, J.J.V., et al., *Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity*. Oncotarget, 2018. **9**(34): p. 23426-23438.
30. Wardill, H.R., et al., *Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms*. Mol Cancer Ther, 2016. **15**(6): p. 1376-86.

31. Logan, R.M., et al., *Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs*. *Cancer Biol Ther*, 2008. **7**(7): p. 1139-45.
32. Logan, R.M., et al., *The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs*. *Cancer Treat Rev*, 2007. **33**(5): p. 448-60.
33. Varatharaj, A. and I. Galea, *The blood-brain barrier in systemic inflammation*. *Brain Behav Immun*, 2017. **60**: p. 1-12.
34. Rochfort, K.D., et al., *Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions*. *PLoS One*, 2014. **9**(7): p. e101815.
35. Lively, S. and L.C. Schlichter, *Microglia Responses to Pro-inflammatory Stimuli (LPS, IFNgamma+TNFalpha) and Reprogramming by Resolving Cytokines (IL-4, IL-10)*. *Front Cell Neurosci*, 2018. **12**: p. 215.
36. Gibson, E.M., et al., *Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment*. *Cell*, 2019. **176**(1-2): p. 43-55.e13.
37. Banjara, M. and C. Ghosh, *Sterile Neuroinflammation and Strategies for Therapeutic Intervention*. *Int J Inflam*, 2017. **2017**: p. 8385961.
38. Dheen, S.T., C. Kaur, and E.A. Ling, *Microglial activation and its implications in the brain diseases*. *Curr Med Chem*, 2007. **14**(11): p. 1189-97.

39. Kirkley, K.S., et al., *Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity*. J Neuroinflammation, 2017. **14**(1): p. 99.
40. Jordan, K.R., et al., *Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities*. Cancer, 2018. **124**(20): p. 3990-3999.
41. Ley, R.E., D.A. Peterson, and J.I. Gordon, *Ecological and evolutionary forces shaping microbial diversity in the human intestine*. Cell, 2006. **124**(4): p. 837-48.
42. Rhee, S.H., C. Pothoulakis, and E.A. Mayer, *Principles and clinical implications of the brain-gut-enteric microbiota axis*. Nat Rev Gastroenterol Hepatol, 2009. **6**(5): p. 306-14.
43. Long-Smith, C., et al., *Microbiota-Gut-Brain Axis: New Therapeutic Opportunities*. Annu Rev Pharmacol Toxicol, 2019.
44. Mayer, E.A., *Gut feelings: the emerging biology of gut-brain communication*. Nat Rev Neurosci, 2011. **12**(8): p. 453-66.
45. Cryan, J.F., et al., *The Microbiota-Gut-Brain Axis*. Physiol Rev, 2019. **99**(4): p. 1877-2013.
46. Sarkar, A., et al., *Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals*. Trends Neurosci, 2016. **39**(11): p. 763-781.
47. Sarathy, J., et al., *The Yin and Yang of bile acid action on tight junctions in a model colonic epithelium*. Physiol Rep, 2017. **5**(10): p. e13294.
48. Dalile, B., et al., *The role of short-chain fatty acids in microbiota-gut-brain communication*. Nat Rev Gastroenterol Hepatol, 2019.
49. Erny, D., et al., *Host microbiota constantly control maturation and function of microglia in the CNS*. Nat Neurosci, 2015. **18**(7): p. 965-77.

50. Braniste, V., et al., *The gut microbiota influences blood-brain barrier permeability in mice*. *Sci Transl Med*, 2014. **6**(263): p. 263ra158.
51. Hoyles, L., et al., *Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier*. *Microbiome*, 2018. **6**(1): p. 55.
52. Fulling, C., T.G. Dinan, and J.F. Cryan, *Gut Microbe to Brain Signaling: What Happens in Vagus*. *Neuron*, 2019. **101**(6): p. 998-1002.
53. Perez-Burgos, A., et al., *The gut-brain axis rewired: adding a functional vagal nicotinic "sensory synapse"*. *Faseb j*, 2014. **28**(7): p. 3064-74.
54. McVey Neufeld, K.A., et al., *The gut microbiome restores intrinsic and extrinsic nerve function in germ-free mice accompanied by changes in calbindin*. *Neurogastroenterol Motil*, 2015. **27**(5): p. 627-36.
55. Zheng, J., et al., *A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae*. *Int J Syst Evol Microbiol*, 2020.
56. McVey Neufeld, K.A., et al., *The microbiome is essential for normal gut intrinsic primary afferent neuron excitability in the mouse*. *Neurogastroenterol Motil*, 2013. **25**(2): p. 183-e88.
57. Suarez, A.N., et al., *Gut vagal sensory signaling regulates hippocampus function through multi-order pathways*. *Nat Commun*, 2018. **9**(1): p. 2181.
58. Breit, S., et al., *Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders*. *Front Psychiatry*, 2018. **9**: p. 44.

59. Sudo, N., et al., *Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice*. J Physiol, 2004. **558**(Pt 1): p. 263-75.
60. de Souza-Talarico, J.N., et al., *Effects of stress hormones on the brain and cognition: Evidence from normal to pathological aging*. Dement Neuropsychol, 2011. **5**(1): p. 8-16.
61. Keller, J., et al., *HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition*. Mol Psychiatry, 2017. **22**(4): p. 527-536.
62. Ouanes, S. and J. Popp, *High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature*. Front Aging Neurosci, 2019. **11**: p. 43.
63. Goh, K.K., et al., *Effect of probiotics on depressive symptoms: A meta-analysis of human studies*. Psychiatry Res, 2019: p. 112568.
64. Liu, P., et al., *Altered microbiomes distinguish Alzheimer's disease from amnesic mild cognitive impairment and health in a Chinese cohort*. Brain Behav Immun, 2019. **80**: p. 633-643.
65. Bajic, J.E., et al., *Neuroimmunological Manifestations of Chemotherapy Exposure: Implications for Mucositis, Glia and Cognition*. J Can Sci Res, 2017. **2**(1): p. 9.
66. Bajic, J.E., et al., *From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation*. Front Behav Neurosci, 2018. **12**: p. 104.
67. Logan, R.M., et al., *Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis*. Cancer Chemother Pharmacol, 2008. **62**(1): p. 33-41.

68. Loman, B.R., et al., *Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice*. *Sci Rep*, 2019. **9**(1): p. 16490.
69. Brandi, G., et al., *Intestinal microflora and digestive toxicity of irinotecan in mice*. *Clin Cancer Res*, 2006. **12**(4): p. 1299-307.
70. Pedroso, S.H., et al., *Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice*. *Microbiology*, 2015. **161**(10): p. 1950-60.
71. Maier, L., et al., *Extensive impact of non-antibiotic drugs on human gut bacteria*. *Nature*, 2018. **555**(7698): p. 623-628.
72. Clarke, G., et al., *Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions*. *Pharmacol Rev*, 2019. **71**(2): p. 198-224.
73. Lin, X.B., et al., *Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats*. *PLoS One*, 2012. **7**(7): p. e39764.
74. Montassier, E., et al., *Chemotherapy-driven dysbiosis in the intestinal microbiome*. *Aliment Pharmacol Ther*, 2015. **42**(5): p. 515-28.
75. Stringer, A.M., et al., *Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases*. *Support Care Cancer*, 2013. **21**(7): p. 1843-52.
76. Stringer, A.M., et al., *Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile*. *Int J Exp Pathol*, 2009. **90**(5): p. 489-99.

77. Stringer, A.M., et al., *Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat*. *Exp Biol Med* (Maywood), 2007. **232**(1): p. 96-106.
78. Stringer, A.M., et al., *Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis*. *Exp Biol Med* (Maywood), 2009. **234**(4): p. 430-41.
79. Stringer, A.M., et al., *Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats*. *Cancer Biol Ther*, 2008. **7**(12): p. 1919-25.
80. Zwieler, J., et al., *Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting*. *PLoS One*, 2011. **6**(12): p. e28654.
81. Chelakkot, C., J. Ghim, and S.H. Ryu, *Mechanisms regulating intestinal barrier integrity and its pathological implications*. *Exp Mol Med*, 2018. **50**(8): p. 103.
82. Savignac, H.M., et al., *Bifidobacteria modulate cognitive processes in an anxious mouse strain*. *Behav Brain Res*, 2015. **287**: p. 59-72.
83. Distrutti, E., et al., *Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP*. *PLoS One*, 2014. **9**(9): p. e106503.
84. Gareau, M.G., et al., *Bacterial infection causes stress-induced memory dysfunction in mice*. *Gut*, 2011. **60**(3): p. 307-17.

85. Akbari, E., et al., *Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial*. *Front Aging Neurosci*, 2016. **8**: p. 256.
86. Roman, E., et al., *Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial*. *Hepatol Commun*, 2019. **3**(5): p. 632-645.
87. Ceccarelli, G., et al., *Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals*. *Nutrients*, 2017. **9**(11).
88. Reininghaus, E.Z., et al., *The Impact of Probiotic Supplements on Cognitive Parameters in Euthymic Individuals with Bipolar Disorder: A Pilot Study*. *Neuropsychobiology*, 2018: p. 1-8.
89. Zhuang, Z.Q., et al., *Gut Microbiota is Altered in Patients with Alzheimer's Disease*. *J Alzheimers Dis*, 2018. **63**(4): p. 1337-1346.
90. Okubo, R., et al., *Impact of chemotherapy on the association between fear of cancer recurrence and the gut microbiota in breast cancer survivors*. *Brain Behav Immun*, 2019.
91. Wardill, H.R. and W.J.E. Tissing, *Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine*. *Curr Opin Support Palliat Care*, 2017. **11**(2): p. 125-132.



92. Hughes, R.L., et al., *The Role of the Gut Microbiome in Predicting Response to Diet and the Development of Precision Nutrition Models. Part II: Results*. Adv Nutr, 2019.
93. Hughes, R.L., et al., *The Role of the Gut Microbiome in Predicting Response to Diet and the Development of Precision Nutrition Models-Part I: Overview of Current Methods*. Adv Nutr, 2019.
94. Kumagai, T., F. Rahman, and A.M. Smith, *The Microbiome and Radiation Induced-Bowel Injury: Evidence for Potential Mechanistic Role in Disease Pathogenesis*. Nutrients, 2018. **10**(10).
95. Li, W., et al., *Gut microbiome and cancer immunotherapy*. Cancer Lett, 2019. **447**: p. 41-47.
96. Montassier, E., et al., *Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection*. Genome Med, 2016. **8**(1): p. 49.
97. Wong, A.C. and M. Levy, *New Approaches to Microbiome-Based Therapies*. mSystems, 2019. **4**(3).
98. Wardill, H.R., et al., *Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients*. EBioMedicine, 2019. **44**: p. 730-740.
99. Cammarota, G., et al., *European consensus conference on faecal microbiota transplantation in clinical practice*. Gut, 2017. **66**(4): p. 569-580.
100. Trubiano, J.A., et al., *Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand*. Intern Med J, 2016. **46**(4): p. 479-93.

101. Quraishi, M.N., et al., *Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection*. Aliment Pharmacol Ther, 2017. **46**(5): p. 479-493.
102. Martins-Teixeira, M.B. and I. Carvalho, *Antitumour anthracyclines: progress and perspectives*. ChemMedChem, 2020.
103. Seigers, R., et al., *Cognitive impact of cytotoxic agents in mice*. Psychopharmacology (Berl), 2015. **232**(1): p. 17-37.
104. Lim, I., et al., *PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain*. Biomed Res Int, 2016. **2016**: p. 6945415.
105. Christie, L.A., et al., *Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy*. Clin Cancer Res, 2012. **18**(7): p. 1954-65.
106. Barry, R.L., et al., *In vivo neuroimaging and behavioral correlates in a rat model of chemotherapy-induced cognitive dysfunction*. Brain Imaging Behav, 2018. **12**(1): p. 87-95.
107. Kesler, S.R. and D.W. Blayney, *Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors*. JAMA Oncol, 2016. **2**(2): p. 185-92.
108. Abal, M., J.M. Andreu, and I. Barasoain, *Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action*. Curr Cancer Drug Targets, 2003. **3**(3): p. 193-203.
109. Callaghan, C.K. and S.M. O'Mara, *Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram*. Behav Brain Res, 2015. **290**: p. 84-9.

110. Fardell, J.E., et al., *The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice.* Psychopharmacology (Berl), 2014. **231**(5): p. 841-52.
111. Cerulla, N., et al., *Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study.* Breast Cancer Res Treat, 2017. **164**(1): p. 179-187.
112. Johnstone, T.C., G.Y. Park, and S.J. Lippard, *Understanding and improving platinum anticancer drugs--phenanthriplatin.* Anticancer Res, 2014. **34**(1): p. 471-6.
113. Shabani, M., et al., *Evaluation of destructive effects of exposure to cisplatin during developmental stage: no profound evidence for sex differences in impaired motor and memory performance.* Int J Neurosci, 2012. **122**(8): p. 439-48.
114. Chiu, G.S., et al., *Pifithrin-mu Prevents Cisplatin-Induced Chemobrain by Preserving Neuronal Mitochondrial Function.* Cancer Res, 2017. **77**(3): p. 742-752.
115. Zhou, W., A. Kavelaars, and C.J. Heijnen, *Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice.* PLoS One, 2016. **11**(3): p. e0151890.
116. Fardell, J.E., et al., *Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity.* Psychopharmacology (Berl), 2012. **220**(1): p. 183-93.

117. Fardell, J.E., et al., *The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy*. Behav Brain Res, 2015. **291**: p. 80-88.
118. Lomeli, N., et al., *Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats*. Free Radic Biol Med, 2017. **102**: p. 274-286.
119. Kaplan, S.V., et al., *Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with Carboplatin*. ACS Chem Neurosci, 2016. **7**(6): p. 689-99.
120. Mu, L., et al., *Impairment of cognitive function by chemotherapy: association with the disruption of phase-locking and synchronization in anterior cingulate cortex*. Mol Brain, 2015. **8**: p. 32.
121. Amidi, A., et al., *Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy*. J Natl Cancer Inst, 2017. **109**(12).
122. Hall, A.G. and M.J. Tilby, *Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies*. Blood Rev, 1992. **6**(3): p. 163-73.
123. Janelins, M.C., et al., *A clinically relevant dose of cyclophosphamide chemotherapy impairs memory performance on the delayed spatial alternation task that is sustained over time as mice age*. Neurotoxicology, 2016. **56**: p. 287-293.
124. Acharya, M.M., et al., *Stem cell transplantation reverses chemotherapy-induced cognitive dysfunction*. Cancer Res, 2015. **75**(4): p. 676-86.

125. Yang, M., et al., *Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits*. *Neurobiol Learn Mem*, 2010. **93**(4): p. 487-94.
126. Florian, S. and T.J. Mitchison, *Anti-Microtubule Drugs*. *Methods Mol Biol*, 2016. **1413**: p. 403-21.
127. Shabani, M., et al., *Profound destructive effects of adolescent exposure to vincristine accompanied with some sex differences in motor and memory performance*. *Can J Physiol Pharmacol*, 2012. **90**(4): p. 379-86.
128. Peters, G.J., *Novel developments in the use of antimetabolites*. *Nucleosides Nucleotides Nucleic Acids*, 2014. **33**(4-6): p. 358-74.
129. Seigers, R., et al., *Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats*. *Behav Brain Res*, 2009. **201**(2): p. 279-84.
130. Lyons, L., et al., *Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy*. *Psychopharmacology (Berl)*, 2011. **215**(1): p. 105-15.
131. Yang, M., et al., *Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro*. *Biochem Pharmacol*, 2011. **82**(1): p. 72-80.
132. ElBeltagy, M., et al., *Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil*. *Behav Brain Res*, 2010. **208**(1): p. 112-7.
133. Bisen-Hersh, E.B., P.N. Himeline, and E.A. Walker, *Effects of early chemotherapeutic treatment on learning in adolescent mice: implications for*

- cognitive impairment and remediation in childhood cancer survivors. Clin Cancer Res, 2013. 19(11): p. 3008-18.*
134. Fardell, J.E., et al., *Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol Biochem Behav, 2010. 97(2): p. 333-9.*
135. Dubois, M., et al., *Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant. Neuropharmacology, 2014. 79: p. 234-48.*
136. Liang, X., et al., *A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur J Med Chem, 2019. 171: p. 129-168.*
137. Bajaj, J.S., et al., *Post-Traumatic Stress Disorder is Associated with Altered Gut Microbiota that Modulates Cognitive Performance in Veterans with Cirrhosis. Am J Physiol Gastrointest Liver Physiol, 2019.*
138. Palomo-Buitrago, M.E., et al., *Glutamate interactions with obesity, insulin resistance, cognition and gut microbiota composition. Acta Diabetol, 2019. 56(5): p. 569-579.*
139. Verdi, S., et al., *An Investigation Into Physical Frailty as a Link Between the Gut Microbiome and Cognitive Health. Front Aging Neurosci, 2018. 10: p. 398.*
140. Anderson, J.R., et al., *A preliminary examination of gut microbiota, sleep, and cognitive flexibility in healthy older adults. Sleep Med, 2017. 38: p. 104-107.*
141. Manderino, L., et al., *Preliminary Evidence for an Association Between the Composition of the Gut Microbiome and Cognitive Function in Neurologically Healthy Older Adults. J Int Neuropsychol Soc, 2017. 23(8): p. 700-705.*

142. Fernandez-Real, J.M., et al., *Gut Microbiota Interacts With Brain Microstructure and Function*. J Clin Endocrinol Metab, 2015. **100**(12): p. 4505-13.

**Table 1**

The neurocognitive side effects of common chemotherapy classes, as determined by clinical and preclinical studies.

Abbreviations: WAIS: Wechsler adult intelligence scale; MWM: Morris water maze; NLR: novel location recognition; NOR: novel object recognition; SRTT: simple reaction time task; 5CSRTT: 5-choice serial reaction time task.

\*Clinical data is only presented when cognitive impairment could be attributed to a defined class of chemotherapy agents.

Cancer Treatment Class	Mechanism of Action	Preclinical data		Clinical data	
		Cognitive domains effected	Cognitive tests used & references	Cognitive effects	Cognitive tests used
Anthracyclines (doxorubicin, epirubicin, daunorubicin)	<ul style="list-style-type: none"> <li>DNA intercalation</li> <li>Inhibition of the topoisomerase II enzyme, disrupting DNA synthesis</li> <li>Induction of oxidative stress [102]</li> </ul>	<ol style="list-style-type: none"> <li>Spatial working memory (short &amp; long term)</li> <li>Recognition memory (short &amp; long term)</li> <li>Contextual memory (long term)</li> </ol>	<ol style="list-style-type: none"> <li>Barnes maze [103] &amp; MWM [104]</li> <li>NLR [105] &amp; NOR [106]</li> <li>Contextual fear test [105]</li> </ol>	Anthracyclines-based chemotherapy is associated with lower verbal memory performance when compared to non-anthracyclines based chemotherapy [107].	Hopkins verbal learning test – revised
Taxanes (paclitaxel, docetaxel)	<ul style="list-style-type: none"> <li>Prevent microtubules from disassociating thereby disrupting</li> </ul>	<ol style="list-style-type: none"> <li>Recognition memory (short term)</li> <li>Inhibitory control</li> </ol>	<ol style="list-style-type: none"> <li>NLR [109] &amp; NOR [110]</li> <li>SRTT[103]</li> </ol>	Taxane-based chemotherapy was associated with the development of symptoms affecting: 1. Processing speed	<ol style="list-style-type: none"> <li>WAIS – digit speed</li> <li>WAIS digit span</li> </ol>




	cellular division [108]			2. Auditive attention 3. Learning where non-taxane based chemotherapy was not [111].	3. CLVT verbal learning
Platinums (carboplatin, cisplatin, oxaliplatin)	<ul style="list-style-type: none"> <li>Interact with nuclear DNA to form inter-strand cross links to distort DNA double helix structure [112]</li> </ul>	<ol style="list-style-type: none"> <li>Spatial working memory (short &amp; long term)</li> <li>Recognition memory (short &amp; long term)</li> <li>Contextual memory (long term)</li> <li>Attention</li> <li>Behavioral flexibility</li> </ol>	<ol style="list-style-type: none"> <li>MWM [113] &amp; Y-maze [114]</li> <li>Social recognition [115], NOR [116] &amp; NLR [117]</li> <li>Contextual fear test [118]</li> <li>5CSRTT [119]</li> <li>Iowa gambling task [120]</li> </ol>	Platinum-based chemotherapy was associated with lower learning and memory when compared to non-chemotherapy treated patients [121].	Rey auditory verbal learning test
Alkylating agents (cyclophosphamide)	<ul style="list-style-type: none"> <li>Covalently bind alkyl groups to DNA nucleotides enabling inter- or intra-strand cross link formation &amp; mispairing of nucleotides [122]</li> </ul>	<ol style="list-style-type: none"> <li>Spatial working memory (short term)</li> <li>Recognition memory (short &amp; long term)</li> <li>Contextual memory (long term)</li> <li>Inhibitory control</li> </ol>	<ol style="list-style-type: none"> <li>Delayed spatial alternation task [123]</li> <li>NLR, temporal order task [124] &amp; NOR [125]</li> <li>Contextual fear test [105]</li> <li>SRTT [103]</li> </ol>	Neurocognitive side effects evident with combination chemotherapy*	-

Vinca alkaloids (vinblastine, vincristine)	<ul style="list-style-type: none"> <li>Prevents polymerisation of tubulin into microtubules [126]</li> </ul>	<ol style="list-style-type: none"> <li>Spatial working memory (short &amp; long term)</li> </ol>	<ol style="list-style-type: none"> <li>MWM [127]</li> </ol>	Neurocognitive side effects evident with combination chemotherapy*	-
Antimetabolites (5-flourouracil, capecitabine, methotraxate)	<ul style="list-style-type: none"> <li>Act as substitutes for essential metabolites, thereby preventing the use of that metabolite in cell growth and function [128]</li> </ul>	<ol style="list-style-type: none"> <li>Spatial working memory (short &amp; long term)</li> <li>Recognition memory (short &amp; long term)</li> <li>Contextual memory (long term)</li> <li>Discrimination learning</li> <li>Inhibitory control</li> <li>Behavioral flexibility</li> </ol>	<ol style="list-style-type: none"> <li>Barnes maze [103] &amp; MWM [129]</li> <li>NLR [130] &amp; NOR [131]</li> <li>Contextual fear test [132]</li> <li>Autoshaping [133]</li> <li>Go/no go task [134]</li> <li>MWM [135]</li> </ol>	Neurocognitive side effects evident with combination chemotherapy*	-
Topoisomerase inhibitors (irinotecan, etoposide)	<ul style="list-style-type: none"> <li>Inhibit the topoisomerase I &amp; II enzymes disrupting DNA synthesis [136]</li> </ul>	<ol style="list-style-type: none"> <li>Spatial working memory (short term)</li> <li>Inhibitory control</li> </ol>	<ol style="list-style-type: none"> <li>Barnes maze [103] SRTT [103]</li> </ol>	Neurocognitive side effects evident with combination chemotherapy*	-

**Figure 1:** The BBB and neuroinflammation in CICI: (1) peripheral inflammatory mediators and the chemotherapy agent present in systemic circulation increase BBB permeability through tight junction disruption and increased caveolae-mediated transcytosis. (2) The mediators and chemotherapy agent cross the BBB and enter the CNS. (3) Proinflammatory cytokine TNF $\alpha$  and the chemotherapy agent activate resident microglia which initiate a neuroinflammatory response. (4) Activated microglia cause activation of astrocytes and together, microglia and astrocytes release proinflammatory cytokines and ROS which contribute to neuroinflammation and further BBB damage. (5) The chemotherapy agent, once present in the CNS, contributes to neuroinflammation and causes direct toxicity to neurons. (6) As a result of neuroinflammation and cytotoxicity neurons are damaged, and apoptosis may occur. Abbreviations: MMPs; matrix metalloproteinases; IL-1 $\beta$ : interleukin-1 beta; IL-6: interleukin-6; TNF $\alpha$ : tumour necrosis factor alpha; CNS: central nervous system; ROS: reactive oxygen species.

**Colour Figures:** we would like to have our image printed in black and white with colour images online only.



**Table 2**

Summary of human studies investigating microbial profiles associated with cognitive performance. Abbreviations; hepatic encephalopathy (HE), post-traumatic stress disorder (PTSD), Alzheimer’s disease (AD), amnesic mild cognitive impairment (aMCI), healthy controls (HC), Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Cambridge Neuropsychological Test Automated Battery (CANTAB-PAL), relative abundance (RA), proton pump inhibitors (PPI).

Study Participants	Cognitive battery tools	Specific microbial findings relating to cognitive performance			Reference
		Microbial diversity and cognitive domains involved	Good cognitive performance	Poor cognitive performance	
93 Veterans with liver cirrhosis with/without HE, 29 of whom were diagnosed with PTSD	- Inhibitory control test - Block design test	GI microbiota composition is associated with executive function and intelligence.	↑ Faecalibacterium RA	↑ Escherichia/Shigella RA ↑ Enterococcus RA	[137]
35 subjects – 19 obese and 16	- Trail making test A & B	GI microbiota composition is associated with	↑ Burkholderiaceae RA	↑ Streptococaceae RA	[138]

non-obese, with similar age and sex.		mental flexibility and processing speeds.	↑ Corynebacteriaceae RA		
97 subjects – 33 AD, 32 aMCI and 32 HC.	- MMSE - MoCA - Clinical dementia rating	AD subjects had lower overall microbial diversity.	↑ Bacteroidetes RA ↑ Ruminococcaceae RA	↑ Enterobacteriaceae RA ↑ Veillonellaceae RA	[64]
1,551 subjects – largely female (90%) and over 40 years of age.	- Verbal Fluency Test - Deary-Liewald - Reaction time test - MMSE - CANTAB-PAL	Poorer reaction times were associated with lower overall microbial diversity.	↑ Burkholderiales RA (In subgroup excluding subjects taking PPIs and antibiotics and dietary index was included as a covariate)	-	[139]
86 subjects – 43 AD and 43 age and gender matched HC.	- MMSE - Activities daily living test	Microbial diversity was altered in AD subjects compared to HC.	-	↑ Ruminococcaceae RA ↓ Lachnospiraceae RA	[89]

37 healthy subjects 50-85 years of age	- Stroop Colour- Word Test	Microbiota composition is associated with cognitive flexibility.	↑ Verrucomicrobia RA (when controlling for carbohydrate intake and hypertension)  ↑ Lentisphaerae RA (independent of carbohydrate intake)	-	[140]
43 healthy subjects 50-85 years of age	- MMSE - Frontal assessment battery - The Hopkins verbal learning test revised - Verbal fluency test	GI microbiota composition is associated with attention, executive function and learning.	↑ Firmicutes RA ↑ Verrucomicrobia RA	↑ Bacteroidetes RA ↑ Proteobacteria RA	[141]
39 subjects – 20 obese and 19	- Trail making test	Actinobacteria RA is associated with	↑ Actinobacteria RA	-	[142]

nonobese all between the ages of 30-65		attention and cognitive flexibility.			
--	--	---	--	--	--